Partial Protection of Mice against Trypanosoma cruzi after Immunizing with the TcY 72 Antigenic Preparation

Gomes, Yara M.; Abath, Frederico G. C.; Nakazawa, Mineo; Minóprio, Paola; Vouldoukis, Ioannis; Monjour, L

doi:10.1590/s0074-02761999000200007

Cited by 6 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…xto +++ 80 post-inoculation (Liew et al 1987 ;Carlomagno et al 1996 ;Gomes et al 1999 ;Leon, Wang and Engman, 2003). Since tripomastigote lysates were used as immunogen in the DTH assay, the positive response observed in Tc13 Tul immunized mice indicates that Tc13 Tul genetic immunization enabled animals to respond to Tc13 antigen concentrations present in the parasite, somehow resembling the response which could be achieved after a natural infection.…”

Section: Discussionmentioning

confidence: 99%

Immunological and pathological responses in BALB/c mice induced by genetic administration ofTc13 Tul antigen ofTrypanosoma cruzi

et al. 2006

View full text Add to dashboard Cite

Tc13 is a trans-sialidase family protein of Trypanosoma cruzi, the aetiological agent of Chagas' disease. Recently, in vitro studies had suggested that Tc13 might participate in the pathogenesis of the disease. In order to study the role of Tc13 antigens in an in vivo model, we administered plasmid DNA encoding a Tc13 antigen from the Tulahuén strain (Tc13 Tul) to BALB/c mice and evaluated the immunological and pathological manifestations as well as the capacity of this antigen to confer protection against T. cruzi infection. Tc13 Tul immunization did not elicit a detectable humoral immune response but induced specific memory T-cells with no capacity to produce IFN-gamma. Five months after DNA-immunization with Tc13 Tul, signs of hepatotoxicity and reactive changes in the heart, liver and spleen were observed in 40-80% of mice. When Tc13 Tul DNA-immunized animals were challenged with trypomastigotes, a significant decrease in parasitaemia in early and late acute phase was observed without modification in the survival rate. Surprisingly, Tc13 Tul-immunized mice chronically infected with T. cruzi showed a decrease in the severity of heart damage. We conclude that, in BALB/c mice, genetic immunization with Tc13 Tul mainly induces immune responses associated with pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunological and pathological responses in BALB/c mice induced by genetic administration ofTc13 Tul antigen ofTrypanosoma cruzi

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Así, se identificó que una fracción flagelar de T. cruzi era capaz de disminuir la parasitemia (16), y más adelante se lograron aislar diferentes glicoproteínas (GP) de la superficie del parásito que exhibieron un buen grado de protección, tales como las GP90, GP70 (17) y las proteínas 45 kDa y de 68 kDa emulsionadas en un derivado de saponina llamado Quil A (18). Incluso, una proteína 72 kDa obtenida a partir de epimastigote generó un título elevado de IgG, inmunidad celular específica y una disminución significativa de la parasitemia (19). También se identificaron los antígenos de la superfamilia de la transialidasa (TS) (737 genes), las mucinas (662 genes), las proteínas de superficie asociadas a mucinas (MASP, 944 genes), GP63 (174 genes) (20), la proteína reguladora del complemento (CRP) (21), la cisteína proteasa lisosomal cruzipaína (Cz) (22), la proteína de unión a calcio flagelar (FCaBP o Tc24) (23,24), GP90, GP82 (25) y TC52 (26).…”

Section: Generalidades Acerca De La Enfermedad De Chagasunclassified

Desarrollo preclínico de vacunas profilácticas contra la Enfermedad de Chagas basadas en Transialidasa.

et al. 2021

View full text Add to dashboard Cite

La Enfermedad de Chagas (ECh), ocasionada por el parásito flagelado Trypanosoma cruzi (T. cruzi), es una de las parasitosis de mayor impacto en la Salud Pública de Latinoamérica. Si bien actualmente existen medidas de prevención como el tamizaje en bancos de sangre, el control a las embarazadas y el control vectorial, aún se requiere de estrategias más eficaces para evitar nuevos casos. Una de estas posibles estrategias es el desarrollo de una vacuna profiláctica contra T. cruzi. Desde el descubrimiento de la enfermedad en 1909, se han evaluado diferentes vacunas experimentales, pero aún no se ha logrado el desarrollo clínico de una formulación efectiva contra el parásito. En este artículo realizamos una revisión bibliográfica acerca de las distintas estrategias de vacunación que se evaluaron hasta la actualidad y, particularmente, el uso de la enzima Transialidasa (TS) como antígeno vacunal. También abordamos distintos aspectos de la superfamilia de la TS, como la clasificación de las distintas proteínas, sus características funcionales y su rol en la infección por T. cruzi. A lo largo de 100 años se han abordado y perfeccionado una gran diversidad de estrategias vacunales contra T. cruzi, lo cual permite augurar el salto desde el campo pre—clínico al desarrollo clínico de una vacuna efectiva en un futuro cercano.

show abstract

“…Gomes and colleagues immunized C57B1/10 mice with an antigenic preparation called TcY 72, obtained when a lysate of T. cruzi Y strain epimastigotes was separated by electrophoresis and a 72 kDa band was isolated by electroelution. They observed the induction of high levels of IgG antibodies, a delayed hypersensitivity reaction after injection of epimastigotes in the legs of the mice, a significant reduction of parasitemia, and a decreased CD4/CD8 ratio in immunized mice [ 22 ], which suggest a possible role for CD8 + subpopulations.…”

Section: Purified Protein Immunizationmentioning

confidence: 99%

Experimental Vaccines against Chagas Disease: A Journey through History

Rodríguez-Morales

Monteón-Padilla

Carrillo-Sánchez

et al. 2015

Journal of Immunology Research

View full text Add to dashboard Cite

Chagas disease, or American trypanosomiasis, which is caused by the protozoan parasite Trypanosoma cruzi, is primarily a vector disease endemic in 21 Latin American countries, including Mexico. Although many vector control programs have been implemented, T. cruzi has not been eradicated. The development of an anti-T. cruzi vaccine for prophylactic and therapeutic purposes may significantly contribute to the transmission control of Chagas disease. Immune protection against experimental infection with T. cruzi has been studied since the second decade of the last century, and many types of immunogens have been used subsequently, such as killed or attenuated parasites and new DNA vaccines. This primary prevention strategy appears feasible, effective, safe, and inexpensive, although problems remain. The objective of this review is to summarize the research efforts about the development of vaccines against Chagas disease worldwide. A thorough literature review was conducted by searching PubMed with the terms “Chagas disease” and “American trypanosomiasis” together with “vaccines” or “immunization”. In addition, reports and journals not cited in PubMed were identified. Publications in English, Spanish, and Portuguese were reviewed.

show abstract

Partial Protection of Mice against Trypanosoma cruzi after Immunizing with the TcY 72 Antigenic Preparation

Cited by 6 publications

References 35 publications

Immunological and pathological responses in BALB/c mice induced by genetic administration ofTc13 Tul antigen ofTrypanosoma cruzi

Immunological and pathological responses in BALB/c mice induced by genetic administration ofTc13 Tul antigen ofTrypanosoma cruzi

Desarrollo preclínico de vacunas profilácticas contra la Enfermedad de Chagas basadas en Transialidasa.

Experimental Vaccines against Chagas Disease: A Journey through History

Contact Info

Product

Resources

About